IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, has received notification from one of its pharmaceutical clients of its decision to stop the screening, randomisation and dosing in a Phase II/III clinical study in Alzheimer’s Disease in which IXICO is providing specialist imaging clinical trial services.
The contract had previously expanded in September 2017 to a value of $7.7 million to the end of 2024. Over the past three years, IXICO has recognised $2.0 million of this total. The cessation of this trial is not expected to materially impact performance in the current financial year. The client’s decision to stop the study was not related to IXICO’s performance. The Company remains on track to deliver double-digit revenue growth, generating revenues in excess of £4.5 million, and meet market expectations for the current financial year.
The Company has a strong order book, a broad pipeline of opportunities and commercial momentum which will support the continued growth of the business beyond the current financial year.
Giulio Cerroni, Chief Executive Officer of IXICO, said: “We continue to provide our analytical services for subjects already enrolled on this clinical trial. We are also working closely with our client to plan patient follow up and data analysis activities as the study is closed down. Whilst it is disappointing that this project will not continue for the full contract term, our broad neurological focus, order book and pipeline mitigates such challenges that can arise in our client’s clinical development programmes.”
Further to the announcement on 3 May 2018 in relation to the placing of new ordinary shares in the Company to raise £5.5 million and the despatch of a related shareholder circular, IXICO plc (AIM: [...]
Commercially-led growth strategy delivers strong H1 performance Oversubscribed capital raise of £5.5m post the period end IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces its unaudited interim results for the [...]
Providing specialist imaging clinical trials services in Huntington’s disease IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announced that it has signed a new contract with a top 10 pharmaceutical company, [...]
IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces that it has signed amendments to current contracts which expand the clinical trial services provided to two biopharmaceutical companies. The change orders have [...]
Oversubscribed placing to raise £5.5 million at 28 pence per share, Related Party Transaction and Notice of General Meeting
Provides platform to accelerate commercial strategy to drive mid-term revenue growth IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, is pleased to announce that it is proposing to raise £5.5 million (before [...]
IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, will announce its interim results for the six months ending 31 March 2018 on Wednesday 23 May 2018. PRESS RELEASE